表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKIs）是EGFR突变的晚期非小细胞肺癌（NSCLC）的一线标准治疗方法。然而，对EGFR-TKIs的抗药性是不可避免的。目前，大多数关于EGFR-TKIs抗药性机制的研究主要集中在NSCLC细胞的自发性抗药性表型上。研究表明，肿瘤微环境（TME）也在NSCLC中介导了EGFR-TKIs的抗药性。肿瘤相关巨噬细胞（TAMs）是NSCLC TME中的中心免疫细胞之一，对介导EGFR-TKIs抗药性起着重要作用。本研究旨在全面回顾目前关于TAM介导EGFR-TKIs抗药性的机制，并讨论将EGFR-TKIs与靶向TAMs治疗相结合的潜在疗效。将EGFR-TKIs与靶向TAMs治疗相结合可能在一定程度上改善EGFR突变的NSCLC的预后。版权所有© 2023年 Cheng，Ge，Yao，Wang，Chen，Zhao，Fang和Ji.

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the first-line standard treatment for advanced non-small cell lung cancer (NSCLC) with EGFR mutation. However, resistance to EGFR-TKIs is inevitable. Currently, most studies on the mechanism of EGFR-TKIs resistance mainly focus on the spontaneous resistance phenotype of NSCLC cells. Studies have shown that the tumor microenvironment (TME) also mediates EGFR-TKIs resistance in NSCLC. Tumor-associated macrophages (TAMs), one of the central immune cells in the TME of NSCLC, play an essential role in mediating EGFR-TKIs resistance. This study aims to comprehensively review the current mechanisms underlying TAM-mediated resistance to EGFR-TKIs and discuss the potential efficacy of combining EGFR-TKIs with targeted TAMs therapy. Combining EGFR-TKIs with TAMs targeting may improve the prognosis of NSCLC with EGFR mutation to some extent.Copyright © 2023 Cheng, Ge, Yao, Wang, Chen, Zhao, Fang and Ji.